InMed Historical Income Statement
| INM Stock | USD 4.95 0.45 10.00% |
Historical analysis of InMed Pharmaceuticals income statement accounts such as Selling General Administrative of 6.3 B or Total Revenue of 5.6 M can show how well InMed Pharmaceuticals performed in making a profits. Evaluating InMed Pharmaceuticals income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of InMed Pharmaceuticals's future profits or losses.
Financial Statement Analysis is much more than just reviewing and examining InMed Pharmaceuticals latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether InMed Pharmaceuticals is a good buy for the upcoming year.
InMed |
About InMed Income Statement Analysis
InMed Pharmaceuticals Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to InMed Pharmaceuticals shareholders. The income statement also shows InMed investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).
InMed Pharmaceuticals Income Statement Chart
Add Fundamental
Other Operating Expenses
Other Operating Expenses is the expense which generally does not depend on sales or production quantities of InMed Pharmaceuticals. It is also known as InMed Pharmaceuticals overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.Cost Of Revenue
Cost of Revenue is found on InMed Pharmaceuticals income statement and represents the costs associated with goods and services InMed Pharmaceuticals provides. Indirect cost, such as salaries, is not included. In other words, cost of revenue is the total cost incurred to obtain a sale. It is more than the traditional cost of goods sold, since it includes specific selling and marketing activities.Total Operating Expenses
The total costs associated with the day-to-day operations of a business, excluding the cost of goods sold but including selling, general, and administrative expenses.Most accounts from InMed Pharmaceuticals' income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into InMed Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in InMed Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. To learn how to invest in InMed Stock, please use our How to Invest in InMed Pharmaceuticals guide.At this time, InMed Pharmaceuticals' Total Operating Expenses is very stable compared to the past year. As of the 18th of January 2025, Total Other Income Expense Net is likely to grow to about 297.5 M, though Operating Income is likely to grow to (6.8 B).
| 2024 | 2025 (projected) | Interest Expense | 86.5K | 153.3K | Depreciation And Amortization | 544.1K | 284.9K |
InMed Pharmaceuticals income statement Correlations
Click cells to compare fundamentals
InMed Pharmaceuticals Account Relationship Matchups
High Positive Relationship
High Negative Relationship
InMed Pharmaceuticals income statement Accounts
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Depreciation And Amortization | 197.0K | 511.8K | 596.0K | 604.5K | 544.1K | 284.9K | |
| Interest Expense | 330.4K | 18.6K | 360.4K | 96.1K | 86.5K | 153.3K | |
| Selling General Administrative | 4.5M | 6.9M | 5.8M | 5.3B | 6.0B | 6.3B | |
| Gross Profit | (197.0K) | 543.5K | 1.4M | 1.1M | 1.3M | 1.3M | |
| Other Operating Expenses | 9.9M | 14.9M | 12.5M | 16.0B | 18.4B | 19.3B | |
| Operating Income | (9.9M) | (13.7M) | (8.2B) | (7.9B) | (7.1B) | (6.8B) | |
| Ebit | (10.0M) | (17.8M) | (11.4M) | (7.7M) | (6.9M) | (6.6M) | |
| Ebitda | (9.8M) | (17.3M) | (10.8M) | (7.1M) | (6.4M) | (6.0M) | |
| Cost Of Revenue | 197.0K | 545.9K | 2.7M | 3.5M | 4.0M | 4.2M | |
| Total Operating Expenses | 9.9M | 14.3M | 9.8M | 9.0B | 10.4B | 10.9B | |
| Income Before Tax | (10.2M) | (18.6M) | (7.9M) | (7.7M) | (6.9M) | (6.6M) | |
| Total Other Income Expense Net | 2.1M | (1.1M) | 588.5K | 246.4M | 283.3M | 297.5M | |
| Net Income | (10.2M) | (18.6M) | (7.9M) | (7.7M) | (6.9M) | (6.6M) | |
| Income Tax Expense | 360.4K | 4.8M | 13.1K | 7.1K | 8.2K | 7.8K | |
| Research Development | 5.3M | 7.3M | 3.7M | 3.8M | 4.3M | 2.3M | |
| Net Income From Continuing Ops | (10.2M) | (18.6M) | (7.9M) | (7.7M) | (6.9M) | (7.3M) | |
| Reconciled Depreciation | 120.9K | 511.8K | 596.0K | 604.5K | 695.2K | 730.0K | |
| Net Income Applicable To Common Shares | (11.9M) | (10.2M) | (18.6M) | (7.9M) | (7.2M) | (7.5M) | |
| Net Interest Income | (344.3K) | 96.1K | 492.4K | 527.9K | 607.1K | 637.4K | |
| Interest Income | 16.0K | 96.1K | 492.4K | 527.9K | 607.1K | 637.4K |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in InMed Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. To learn how to invest in InMed Stock, please use our How to Invest in InMed Pharmaceuticals guide.You can also try the Global Correlations module to find global opportunities by holding instruments from different markets.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of InMed Pharmaceuticals. If investors know InMed will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about InMed Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share 253.44 | Revenue Per Share | Quarterly Revenue Growth (0.45) | Return On Assets | Return On Equity |
The market value of InMed Pharmaceuticals is measured differently than its book value, which is the value of InMed that is recorded on the company's balance sheet. Investors also form their own opinion of InMed Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is InMed Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because InMed Pharmaceuticals' market value can be influenced by many factors that don't directly affect InMed Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between InMed Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if InMed Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, InMed Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.